Drug Profile
AZD 2820
Alternative Names: AZD-2820Latest Information Update: 13 Oct 2015
Price :
$50
*
At a glance
- Originator AstraZeneca; Palatin Technologies
- Developer AstraZeneca
- Class Obesity therapies; Peptides
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity